Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epidemiologic Liver Outcomes Retrospective Study to Confirm The Prognostic Value of the FibroNest Digital Pathology Fibrosis Biomarker (Ph-FCS) in Patients With MASLD (DPAILO-1)

NCT06344364 is registered in ClinicalTrials.gov with PharmaNest, Inc as lead sponsor.

NCT NCT06344364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06344364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epidemiologic Liver Outcomes Retrospective Study to Confirm The Prognostic Value of the FibroNest Digital Pathology Fibrosis Biomarker (Ph-FCS) in Patients With MASLD (DPAILO-1)
Lead sponsor
PharmaNest, Inc
Phase
Observational
Overall status
Completed
Start date
September 1, 2025
Completion date
August 15, 2026
Enrollment
1,241 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatotic liver disease